Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology

被引:34
作者
Hristova-Panusheva, Kamelia [1 ]
Xenodochidis, Charilaos [1 ]
Georgieva, Milena [2 ]
Krasteva, Natalia [1 ]
机构
[1] Bulgarian Acad Sci, Inst Biophys & Biomed Engn, Acad Georgi Bonchev Str Bl 21, Sofia 1113, Bulgaria
[2] Bulgarian Acad Sci, Inst Mol Biol Acad R Tsanev, Acad Georgi Bonchev Str,Bl 21, Sofia 1113, Bulgaria
关键词
nanotechnology; site-specific cancer therapy; personalized oncomedicine; cancer-cell-targeted nanomedicines; tumour microenvironment-targeted nanomedicines; BREAST-CANCER; IN-VITRO; GOLD NANOPARTICLES; TUMOR VASCULATURE; THERAPY; NANOMEDICINE; DOXORUBICIN; NANOTHERAPEUTICS; INHIBITION; DENDRIMER;
D O I
10.3390/ph17060677
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nanotechnology has emerged as a transformative force in oncology, facilitating advancements in site-specific cancer therapy and personalized oncomedicine. The development of nanomedicines explicitly targeted to cancer cells represents a pivotal breakthrough, allowing the development of precise interventions. These cancer-cell-targeted nanomedicines operate within the intricate milieu of the tumour microenvironment, further enhancing their therapeutic efficacy. This comprehensive review provides a contemporary perspective on precision cancer medicine and underscores the critical role of nanotechnology in advancing site-specific cancer therapy and personalized oncomedicine. It explores the categorization of nanoparticle types, distinguishing between organic and inorganic variants, and examines their significance in the targeted delivery of anticancer drugs. Current insights into the strategies for developing actively targeted nanomedicines across various cancer types are also provided, thus addressing relevant challenges associated with drug delivery barriers. Promising future directions in personalized cancer nanomedicine approaches are delivered, emphasising the imperative for continued optimization of nanocarriers in precision cancer medicine. The discussion underscores translational research's need to enhance cancer patients' outcomes by refining nanocarrier technologies in nanotechnology-driven, site-specific cancer therapy.
引用
收藏
页数:25
相关论文
共 164 条
[1]   Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles [J].
Abadeer, Nardine S. ;
Murphy, Catherine J. .
JOURNAL OF PHYSICAL CHEMISTRY C, 2016, 120 (09) :4691-4716
[2]  
Abramson R.G., 2018, Overview of Targeted Therapies for Cancer
[3]   Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer [J].
Adiseshaiah, Pavan P. ;
Crist, Rachael M. ;
Hook, Sara S. ;
McNeil, Scott E. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (12) :750-765
[4]   The future of precision medicine in oncology [J].
Al Meslamani, Ahmad Z. .
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2023, 8 (01) :43-47
[5]   Cationic Poly-L-lysine Dendrimer Complexes Doxorubicin and Delays Tumor Growth in Vitro and in Vivo [J].
Al-Jamal, Khuloud T. ;
Al-Jamal, Wafa' T. ;
Wang, Julie T. -W. ;
Rubio, Noelia ;
Buddle, Joanna ;
Gathercole, David ;
Zloh, Mire ;
Kostarelos, Kostas .
ACS NANO, 2013, 7 (03) :1905-1917
[6]   Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo [J].
Alibolandi, Mona ;
Taghdisi, Seyed Mohammad ;
Ramezani, Pouria ;
Shamili, Fazileh Hosseini ;
Farzad, Sara Amel ;
Abnous, Khalil ;
Ramezani, Mohammad .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) :352-364
[7]  
[Anonymous], ABOUT US
[8]  
[Anonymous], About Us
[9]  
[Anonymous], 2018, About Us
[10]  
Atlihan-Gundogdu E, 2020, J PHARM INVEST, V50, P349